Eli Lilly says retatrutide shows more weight loss compared to Ozempic
WCNC CharlotteOctober 28, 2026
Originally published by WCNC Charlotte. The summary below is provided for informational purposes. Read the full article on their website.
Eli Lilly's experimental drug retatrutide showed greater reduction in A1C and double the average weight loss in a head-to-head clinical study against Ozempic.
Read the complete story on the original publisher's website
Read the Full Story at WCNC Charlotte